

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Laekna, Inc.

來凱醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2105)

VOLUNTARY ANNOUNCEMENT

POSITIVE TOPLINE RESULTS FROM U.S. PHASE I SAD STUDY OF LAE102 SHOWED ENCOURAGING TRENDS TOWARD LEAN MASS INCREASE AND FAT MASS REDUCTION

This announcement is made by Laekna, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board (the “**Board**”) of directors of the Company (the “**Directors**”) is pleased to announce that the Group, in collaboration with Eli Lilly and Company, has successfully completed the Phase I single ascending dose study (the “**U.S. SAD Study**”) of LAE102 in the U.S. The U.S. SAD Study was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LAE102 administered via both subcutaneous and intravenous routes in healthy postmenopausal women with an average BMI of 26.99 kg/m².

Consistent with the prior safety profile of LAE102, the U.S. SAD Study demonstrated a well-tolerated safety profile, with no serious adverse events reported.

The U.S. SAD Study demonstrated encouraging trends in body composition improvements following administration of a single dose. Dose-dependent effects on lean body mass increase and fat mass reduction were observed. On Day 29 following a single dose of LAE102, the group with the highest exposure exhibited a 5.06% increase in mean lean body mass from baseline (placebo group has 1.34% reduction from baseline) and a 0.12% decrease in mean fat mass from baseline (placebo group has 2.11% increase from baseline). Single doses of LAE102 resulted in significant and sustained increases in activin A levels, indicating robust target engagement. The duration of target engagement correlated with the dose level. The Group plans to present the detailed study results at an upcoming scientific conference.

These positive results add to a growing body of data supporting LAE102 as a therapeutic approach to cardiometabolic diseases. The Group is actively planning Phase 2 trials to evaluate LAE102 as an add-on therapy to incretins in patients with higher BMI and related comorbidities.

Currently, the Group is in active discussions with potential partners to accelerate the global development and commercialization of LAE102. The Group aims to bring this precision therapy to overweight and obese patients in need of novel treatment options to achieve quality weight control.

About LAE102

LAE102 is an internally discovered monoclonal antibody selectively targeting ActRIIA, a receptor that plays an important role in muscle regeneration and lipid metabolism. In the pre-clinical models, LAE102 has been shown to increase lean mass and decrease fat mass. In combination with GLP-1 receptor agonist, LAE102 can further reduce fat mass and significantly regain the lean mass loss induced by GLP-1 receptor agonists. These findings position LAE102 as a promising drug candidate for achieving quality weight control.

RISK WARNING

LAE102 MAY NOT ULTIMATELY BE SUCCESSFULLY DEVELOPED AND COMMERCIALIZED. THE COMPANY'S SHAREHOLDERS AND POTENTIAL INVESTORS ARE REMINDED TO EXERCISE CAUTION WHEN DEALING IN THE SECURITIES OF THE COMPANY.

By Order of the Board
Laekna, Inc.
Dr. LU Chris Xiangyang
Chairman

Hong Kong, March 10, 2026

As at the date of this announcement, the Board comprises Dr. LU Chris Xiangyang, Ms. XIE Ling and Dr. GU Xiang-Ju Justin as executive Directors; Dr. WANG David Guowei and Mr. SUN Yuan as non-executive Directors; and Dr. YIN Xudong, Dr. LI Min and Mr. ZHOU Jian as independent non-executive Directors.